Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086695 | 0.82 | TSHR (0.31) | ALDH1A1ATML3MBTL1KDM4ELMNA | |
| SCHEMBL12410714 | 0.82 | ALDH1A1 (0.41) | ALDH1A1ATML3MBTL1LMNA | |
| SCHEMBL9818987 | 0.79 | RET (0.30) | — | |
| SCHEMBL12410717 | 0.79 | KMT2A (0.32) | LMNA | |
| SCHEMBL404126 | 0.74 | — | — | |
| SCHEMBL1485662 | 0.69 | SRC (0.35) | ALDH1A1KDM4E | |
| SCHEMBL403843 | 0.69 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL12556553 | 0.69 | — | — | |
| SCHEMBL30054311 | 0.67 | NPC1 (0.38) | ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL2930313 | 0.66 | ALDH1A1 (0.31) | ALDH1A1KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | Epiphany Biosciences ,Inc. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | PNP, TYMP, ENTPD5 | ALDH1A1 3202/4885ATM 1808/4885L3MBTL1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.